AnaptysBio Management

Management Kriterienprüfungen 3/4

AnaptysBio CEO ist Dan Faga , ernannt in Mar 2022, hat eine Amtszeit von 2.67 Jahren. Die jährliche Gesamtvergütung beträgt $7.46M , bestehend aus 8.6% Gehalt und 91.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.33% der Aktien des Unternehmens, im Wert von $8.71M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.7 Jahre bzw. 3.7 Jahre.

Wichtige Informationen

Dan Faga

Geschäftsführender

US$7.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts8.6%
Amtszeit als Geschäftsführer2.7yrs
Eigentum des Geschäftsführers1.3%
Durchschnittliche Amtszeit des Managements2.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder3.7yrs

Jüngste Management Updates

Recent updates

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Nov 01

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 15

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

Jul 08

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 22
News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

May 12
Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Feb 22
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Oct 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

May 24
AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%

Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Apr 27
Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Jan 10
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial

Oct 05

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Sep 14
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

AnaptysBio sells royalties from GSK-partnered Zejula for $45M

Sep 12

AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

Sep 01
AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans

AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%

Aug 31

AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M

Aug 08

Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

May 10
Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

Mar 16
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

Nov 11
AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Jul 28
AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business

Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

May 09
Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

AnaptysBio EPS beats by $0.03, beats on revenue

May 04

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dan Faga im Vergleich zu den Einnahmen von AnaptysBio verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

-US$170m

Mar 31 2024n/an/a

-US$163m

Dec 31 2023US$7mUS$641k

-US$164m

Sep 30 2023n/an/a

-US$148m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$25mUS$474k

-US$129m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$108m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$310kn/a

-US$58m

Vergütung im Vergleich zum Markt: DanDie Gesamtvergütung ($USD7.46M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD3.24M).

Entschädigung vs. Einkommen: DanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.


Geschäftsführer

Dan Faga (44 yo)

2.7yrs

Amtszeit

US$7,461,920

Vergütung

Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and is its President and Chief Executive Off...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Daniel Faga
President2.7yrsUS$7.46m1.33%
$ 8.7m
Eric Loumeau
Chief Legal Officer6.3yrsUS$2.26m0.011%
$ 70.3k
Paul Lizzul
Chief Medical Officer4.3yrsUS$2.44m0.051%
$ 333.8k
Dennis Mulroy
Chief Financial Officer4.3yrsUS$1.81m0.016%
$ 102.9k
Beth Mueller
Senior Vice President of Human Resources5.1yrskeine Datenkeine Daten
Martin Dahl
Senior Vice President of Research2.8yrskeine Datenkeine Daten
Benjamin Stone
Chief Business Officerless than a yearkeine Datenkeine Daten
Douglas Rich
Senior Vice President of CMC1.8yrskeine Datenkeine Daten
Monique Da Silva
Senior Vice President of Corporate Affairsless than a yearkeine Datenkeine Daten
Priya Raina
Senior Vice President of Clinical Operationsless than a yearkeine Datenkeine Daten
Min Bao
Senior Vice President of Clinical Developmentless than a yearkeine Datenkeine Daten

2.7yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: ANABDas Führungsteam des Unternehmens gilt als erfahren (2.7 Jahre durchschnittliche Betriebszugehörigkeit).


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Daniel Faga
President3yrsUS$7.46m1.33%
$ 8.7m
John Orwin
Independent Chairman of the Board1.2yrsUS$338.08k0.011%
$ 72.3k
Hollings Renton
Lead Independent Director9.4yrsUS$342.38k0.0065%
$ 42.3k
John Schmid
Independent Director9.4yrsUS$335.38k0.013%
$ 84.5k
Dennis Fenton
Independent Director6.7yrsUS$331.88k0.0065%
$ 42.3k
Magda Marquet
Independent Director3.8yrsUS$318.38k0.013%
$ 84.5k
Oleg Nodelman
Independent Director3.6yrskeine Datenkeine Daten
J. Ware
Independent Director7.3yrsUS$338.38k0.025%
$ 162.6k
Rita Jain
Independent Director1.6yrsUS$495.60k0.015%
$ 98.3k
Dolca Thomas
Member of Scientific Advisory Board1.8yrskeine Datenkeine Daten
Luisa Salter-Cid
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
John Monroe
Member of Scientific Advisory Boardno datakeine Datenkeine Daten

3.7yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: ANABDie Vorstandsmitglieder gelten als erfahren (3.7 Jahre durchschnittliche Amtszeit).